Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Global collaboration in biomarker-driven clinical trials at ESMO 2024

Eva Ciruelos • 15 Sep 2024
ESMO 2024
General

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, emphasizes the significance of the European Society for Medical Oncology (ESMO) Congress in delivering pivotal updates and preliminary data from practice-changing clinical trials, particularly those presented in presidential symposiums. She highlights Europe’s leadership in clinical research and the growing importance of global collaboration, especially in trials based on biomarkers, as precision medicine continues to advance. This collaborative approach is crucial for achieving the best outcomes for patients in the era of individualized medicine. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Ciruelos

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
1:43
ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer
Eva Ciruelos • 15 Sep 2024
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
0:42
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
Eva Ciruelos • 15 Sep 2024
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
1:33
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
Eva Ciruelos • 15 Sep 2024
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
0:44
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
Eva Ciruelos • 31 May 2024

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026
The content of VJOncology is intended for healthcare professionals